November 14, 2014 - Metabolix, Inc. (NASDAQ:YTEN) has filed a financial statement reporting Disposal Group Including Discontinued Operation Revenue of $434,000 USD.

Period EndPeriodValue
2014-09-30 2014-Q3 434,000

Other Interesting Charts

Cost Of Revenue Research And Development Expenses - Costs And Expenses - Deferred Tax Assets Capitalized Research And Development Expenses - Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost - Effective Income Tax Rate Reconciliation Nondeductible Expense - Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost - Income Tax Expense Benefit - Increase Decrease In Deferred Revenue - Increase Decrease In Prepaid Deferred Expense And Other Assets - Operating Leases Rent Expense Net - Other Nonoperating Income Expense - Prepaid Expense And Other Assets Current - Revenue From Grants - Revenue From Related Parties - Revenue Product Sales To Related Party - Revenues - Sales Revenue Net - Selling General And Administrative Expense - Stock Offering Costs Remaining In Account Payable And Accrued Expenses -

Related News Stories

Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q2 2018 Results - Earnings Call Transcript

2018-08-10 seekingalpha
Yield10 Bioscience, Inc. (NASDAQ:YTEN) Q2 2018 Results Earnings Conference Call August 9, 2018 4:30 PM ET (0-1)

Arcadia Biosciences:  A Speculative Pure-Play In The Genome Editing Agricultural Space

2018-07-16 seekingalpha
I highlight a number of reasons why I've taken a speculative position in RKDA, including commercialization prospects and cash on hand relative to historical burn rates. (5-3)

CUSIP: 591018809